Brief: Axsome Therapeutics Q3 Net Income USD -64.602 Million
Nov 12 (Reuters) - Axsome Therapeutics Q3 operating expenses USD 167.386 million. * Q3 pretax profit USD -64.602 million * Q3 basic EPS USD -1.34 * Q3 operating income USD -62.624 million
Recent news on Axsome Therapeutics
See all newsUS RESEARCH ROUNDUP-Bright Minds Biosciences, Marvell Technology, Oracle Corporation
Axsome Therapeutics Q3 revenue rises on Auvelity and Sunosi
US RESEARCH ROUNDUP-Apple, Kaiser Aluminum, Reliance
Axsome Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Axsome Therapeutics Q2 revenue rises on AUVELITY growth